Brought to you by 
Bayer & Pharmaceutical Proteins: alpha-1-proteinase inhibitor
13 Jul 1999
Executive Summary
Bayer AG and Pharmaceutical Proteins Ltd (transgenic livestock) will develop a genetically-engineered alpha-1-proteinase inhibitor (alpha-1-PI) to treat pulmonary emphysema.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Transgenics
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer & Pharmaceutical Proteins: alpha-1-proteinase inhibitor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice